<DOC>
	<DOCNO>NCT01039038</DOCNO>
	<brief_summary>The objective trial evaluate feasibility dose increase boost curietherapy PDR ( least 40 Gy D95 ) associate extern radiotherapy ( 34 Gy ) intermediate risk prostate cancer .</brief_summary>
	<brief_title>Feasibility Study Dose Increase Boost Curietherapy Pulse Dose Rate ( PDR ) Associated With Extern Radiotherapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age ≥ 50 year ≤ 75 year Life expectancy &gt; 10 year Localized prostatic adenocarcinoma histologically proven Intermediate risk cancer ( T2b PSA 10 20 Gleason = 7 ( 3+4 ) accord Amico criterion Metastasis pelvic pathologic ganglion ( ≥ 10 mm ) absence OMS &lt; 2 No previous treatment radiotherapy and/or curietherapy Hormonotherapy authorize study Rectal ureterovesical pathology Signed informed consent Social security system affiliation Individual deprive liberty place authority tutor . No anesthesia contraindication Adenocarcinoma histologically prove Metastases presence Pathological node presence ( ≥ 10 mm ) Prior prostate endoscopic resection history malignancy except appropriately treat superficial basal cell skin cancer Medical contraindication anesthesia Patients uncontrolled psychiatric disease medical disease incompatible protocol Impossibility respect medical followup protocol geographical , social psychic reason</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>prostate</keyword>
	<keyword>curietherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>intermediate risk</keyword>
</DOC>